全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Patricia Soetekouw , Carla van Herpen ...
来源:[J].Clinical Therapeutics(IF 2.23), 2016, Vol.38 (10), pp.2286-2299Elsevier
摘要:Abstract(#br)Purpose(#br)The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the pote...
作者:Patricia Soetekouw , Sarah Slater ...
来源:[J].Advances in Therapy(IF 2.125), 2015, Vol.32 (6), pp.510-522Springer
摘要:Abstract(#br) Background(#br)The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA -mutated ovarian and breast cancer....
作者:Patricia Soetekouw , Rob L. Jansen ...
来源:[J].Cancer Immunology, Immunotherapy(IF 3.637), 2014, Vol.63 (5), pp.449-458Springer
摘要:Abstract(#br) Introduction(#br)Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit f...
作者:Patricia Soetekouw , Morten Mau-Sørensen ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2015, Vol.76 (4), pp.723-729Springer
摘要:Abstract(#br) Background(#br)The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA -mutated cancer. This Phase I, open-label, three-part study (Parts A–C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×